New technologies offer hope for more effective treatments for malignant pleural mesothelioma and other hard-to-treat cancers. One innovation is the use of 3D printing and optical scanning. These new technologies refine photodynamic therapy, a promising approach for mesothelioma management. Photodynamic therapy uses the power of light to target and destroy[…]
Mesothelioma
Ipilimumab and Nivolumab Can Improve Survival in Mesothelioma Patients
Mesothelioma is a rare and tough cancer to treat and is usually linked to asbestos exposure. Scientists are continually exploring new ways to treat it, and one promising method is using the combination of the two drugs nivolumab and ipilimumab. A new study looks at what these drugs do and[…]
Mesothelin Could Be Used to Improve Mesothelioma Treatment
Mesothelioma is a hard cancer to treat and understand. Understanding protein expressed by mesothelioma cells could potentially help. This protein may be a clue to the cancer, but an easier way to check for it in a lab needs to be found. In the study, scientists dig into mesothelin, see[…]
Radiomics Can Be Used to Improve Mesothelioma Treatment
Malignant mesothelioma is a challenging cancer to treat. New therapies like T cell receptor fusion constructs (TRuCs) show promise. Identifying which patients will benefit from these treatments is important. Radiomics, a field that extracts data from medical images, offers a potential solution. Radiomics may predict treatment responses based on imaging[…]
A Type of T Cell Therapy is Showing Promising Results for Mesothelioma
A clinical trial testing a new type of cell therapy for mesothelioma is actively recruiting patients at sites across the country, including Moffitt Cancer Center in Tampa, Florida. The trial is early stage. The therapy, called Synkir-110, is a lab-engineered cell treatment designed to target mesothelin, a protein found on[…]
A New Guideline for Surgery has Been Created for Mesothelioma
A national panel of 15 mesothelioma specialists across surgery, medical oncology, radiation oncology, and pathology reached a consensus and issued new guidelines for surgery. The experts reviewed 116 studies and data from 630 mesothelioma surgeries between 2015 and 2025. After three rounds of formal voting, the panel challenged reluctance to[…]
RSO-021 Controlled Mesothelioma in Two-Thirds of Patients in Study
A new mesothelioma drug controlled the disease in two out of three patients through 12 weeks of treatment. Researchers say it turns cancer’s own defenses against it. Teams at the University of Vermont and University of Leicester led the small, early-phase trial. Their findings were published July 14 in the[…]
Mesothelioma Cells are Able to Get Around Different Types of Treatment
Mesothelioma cells have a survival trick. When researchers exposed them to an experimental drug that targeted one of the cancer’s main growth switches, the cells did not die. Instead, they found a way around the drug’s effect. A new study in the journal Nature Structural & Molecular Biology has uncovered[…]
Targeting the Collagen Receptor uPARAP to Treat Mesothelioma
Mesothelioma, a cancer with low survival rates, is still a major problem. A major cause of the cancer is asbestos exposure. A new study focuses on a possible treatment target for mesothelioma. The main focus of researchers in the study is the collagen receptor uPARAP. Mesothelioma is mainly caused by[…]
Diagnosing Mesothelioma
Mesothelioma is a challenging cancer to diagnose, and a recent study highlighted a problem with diagnosing the disease called overdiagnosis. This happens when tumors are mistaken for mesothelioma, leading to big challenges in treatment. The study suggests that doctors need to think beyond just using lab tests for diagnosis. The[…]
Skip to content